Table 2.
Competing risk factor analysis for VTE
| Variable | SHR | 95% Confidence interval | p-valuea) |
|---|---|---|---|
| Age > 60 yr | 2.08 | 1.06-4.09 | 0.03 |
| Sex (female) | 0.89 | 0.44-1.77 | 0.73 |
| Smoking | 1.15 | 0.57-2.30 | 0.69 |
| Alcohol | 0.89 | 0.45-1.77 | 0.75 |
| ECOG ≥ 2 | 2.09 | 0.97-4.52 | 0.06 |
| Body mass index ≥ 25 kg/m2 | 5.39 | 0.94-31.10 | 0.06 |
| B Symptom | 1.31 | 0.63-2.75 | 0.47 |
| Stage III/IV | 3.31 | 1.55-7.09 | < 0.01 |
| No. of extranodal site ≥ 2 | 2.88 | 1.47-5.66 | < 0.01 |
| Increased LDH | 1.63 | 0.82-3.26 | 0.17 |
| IPI H/HI | 2.60 | 1.33-5.10 | < 0.01 |
| Bone marrow involvement | 1.36 | 0.49-3.79 | 0.55 |
| Hemoglobin < 10 g/dL | 1.58 | 0.70-3.55 | 0.27 |
| Platelet ≥ 350,000×109/L | 1.41 | 0.55-3.58 | 0.48 |
| WBC > 11,000/mm3 | 2.78 | 1.12-6.86 | 0.03 |
| Radiotherapy | 1.16 | 0.44-3.11 | 0.76 |
| Surgery | 0.89 | 0.32-2.50 | 0.83 |
| Khorana score ≥ 3 | 1.96 | 0.62-6.19 | 0.25 |
| PAI ≥ median value | 1.58 | 0.97-2.58 | 0.06 |
| RANTES ≥ median value | 1.78 | 1.09-2.91 | 0.02 |
| IL-10 ≥ median value | 2.48 | 1.47-4.17 | < 0.01 |
| IP-10 ≥ median value | 1.80 | 1.11-2.95 | 0.02 |
| IL-6 positive | 2.29 | 1.33-3.96 | < 0.01 |
| TNF-α ≥ 0.285 pg/mL | 0.77 | 0.46-1.29 | 0.32 |
VTE, venous thromboembolism; SHR, sub-distributional hazard ratio; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IPI, International Prognostic Index; H, high; HI, high-intermediate; WBC, white blood cell; PAI, plasminogen activator inhibitor-1; RANTES, regulated on activation, normal T cell expressed and secreted, IL, interleukin; IP, interferon gamma-induced protein; TNF, tumor necrosis factor.
a)
Gray’s test.